RBC Capital Reiterates Outperform on Intra-Cellular Therapies, Maintains $86 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a price target of $86.
April 03, 2024 | 12:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital maintains an Outperform rating on Intra-Cellular Therapies with a price target of $86.
The reiteration of an Outperform rating and the maintenance of a high price target by a reputable analyst like Brian Abrahams from RBC Capital could positively influence investor sentiment towards Intra-Cellular Therapies. This endorsement suggests confidence in the company's future performance and growth prospects, potentially leading to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100